vimarsana.com

Page 2 - Genomics Data Science News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Define Tech and CloudCIX to Support Genomics Research Across 7 Universities in Ireland

Trinity researchers secure government funding for next generation therapies for incurable cancers

These updates are republished press releases and communications from members of the Science|Business Network Trinity researchers secure government funding for next generation therapies for incurable cancers Researchers at the Trinity Translational Medicine Institute (TTMI) are part of a successful consortium to secure €6.8M government funding as part of a 3-year, €10.5M programme to develop next generation cell therapies for cancer. The HEALED consortium is one of 29 projects that the government has funded under the Disruptive Technologies Innovation Fund (DTIF) which is managed and funded through the Department of Enterprise and Innovation (DBEI) in Ireland. The research team at TTMI at St James’s Hospital have partnered with RemedyBio, aCGT Vector DAC and the SFI Centre for Research Training (CRT) in Genomics Data Science at NUIG to create the HEALED Consortium

Scientists identify genomic signatures of long-term survival in luminal breast cancer patients

Scientists identify genomic signatures of long-term survival in luminal breast cancer patients Researchers at NUI Galway have identified genomic signatures in women developing the most common type of breast cancer that can be associated with long-term survival. The NUI Galway team analyzed the genomes of breast cancer patients to look for associations with survival rates using advanced statistical techniques. Carried out by Lydia King during her studies in NUI Galway s MSc in Biomedical Genomics programme, the research has been published in the international journal PLOS ONE. Early detection by national screening programmes and timely treatment for patients diagnosed with luminal types of breast cancer have resulted in excellent prognoses with survival rates of over 80% within five years of treatment. The challenge of long-term survival however is not as well understood and studies have shown that more than half of all recurrences for luminal breast cancers takes place after t

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.